{
    "clinical_study": {
        "@rank": "104331", 
        "arm_group": {
            "arm_group_label": "Open Label", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive a subretinal injection of 0.10 ml of the rAAV2.REP1 vector drug substance (10e11 AAV2 genome particles). It is a colourless opalescent frozen liquid with no visible particles. Each patient will be given a one-time dose in one eye.\nIt is the same vector used in the United Kingdom Phase I trial logged at: http://clinicaltrials.gov/ct2/show/NCT01461213."
        }, 
        "brief_summary": {
            "textblock": "A project has been developed in Edmonton, Alberta, Canada to enable male patients with\n      choroideremia to access a clinical trial that replaces the defective gene with a normal\n      copy. This experiment is designed to show that the transfer of a normal copy of the gene to\n      the eye is not only safe but may improve the sight of patients. Only Canadian subjects who\n      meet criteria will be recruited."
        }, 
        "brief_title": "An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Choroideremia", 
        "condition_browse": {
            "mesh_term": "Choroideremia"
        }, 
        "detailed_description": {
            "textblock": "This is an open label study involving a total of 12 male patients. Screening and patient\n      medical records will determine patient eligibility. Patients will receive a subretinal\n      injection of the rAAV2.REP1 vector by a trained vitreoretinal surgeon in one eye. Each\n      patient will be followed up for 24 months after treatment to assess the primary and\n      secondary endpoints of this study using a number of outcome measures. However, further\n      follow-up will continue after the study on an annual basis for a minimum of ten years. Data\n      will continue to be analyzed by members of the study group after this study is complete."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The research subject is willing and able to give informed consent for participation\n             in the study.\n\n          -  Male aged 18 years or above.\n\n          -  Diagnosed with choroideremia (with genotyping or evidence of lack of the gene product\n             with immunohistochemistry) and in good health.\n\n          -  Active degeneration of the retina (the expectation of significant decline in visual\n             function without any intervention over the subsequent 5 years) with OCT (optical\n             coherent tomography) changes visible within the macula.\n\n          -  Willingness to allow his general physician and ophthalmologist, if appropriate, to be\n             notified of participation in the study.\n\n        Exclusion Criteria:\n\n        The participant may not enter the study if ANY of the following apply.\n\n          -  Female or child research subject (under the age of 18).\n\n          -  Men unwilling to use barrier contraception methods, if relevant.\n\n          -  Previous history of retinal surgery or ocular inflammatory disease (uveitis).\n\n          -  Grossly asymmetrical retinal disease or other ocular morbidity which might confound\n             adopting the fellow eye as a long-term comparator.\n\n          -  Any other significant systemic disease or disorder which, in the opinion of the\n             investigator, may either put the research subject at risk because of participation in\n             the study, or may influence the result of the study, or the research subject's\n             ability to participate in the study. This would include a contraindication to oral\n             prednisolone, such as a history of gastric ulcer).\n\n          -  Research subjects who have participated in another research study involving an\n             investigational product within the past year."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077361", 
            "org_study_id": "Pro00028599", 
            "secondary_id": "File # 9427-U0180-84C"
        }, 
        "intervention": {
            "arm_group_label": "Open Label", 
            "description": "No additional details needed.", 
            "intervention_name": "rAAV2.REP1 vector", 
            "intervention_type": "Genetic"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "choroideremia", 
            "gene therapy", 
            "gene transfer"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "link": [
            {
                "description": "Study Website: Click here for more information about the study.", 
                "url": "http://www.chmgenetherapy.ca/"
            }, 
            {
                "description": "Choroideremia Overview", 
                "url": "http://ffb.ca/eye_conditions/choroideremia.html"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Edmonton", 
                    "country": "Canada", 
                    "state": "Alberta", 
                    "zip": "T6G 2E1"
                }, 
                "name": "University of Alberta"
            }, 
            "investigator": [
                {
                    "last_name": "Ian M MacDonald, MD, CM", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Tania Bubela, PhD, LLB", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Elena Posse de Chaves, PhD(Hons)", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yves Sauve, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthew Tennant, MD, FRCSC", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Riz Somani, MD, FRCSC", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Miguel Seabra, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Robert MacLaren, DPhil FRCS FRCOphth", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein-1 (REP1)", 
        "overall_contact": {
            "email": "scchan@ualberta.ca", 
            "last_name": "Stephanie Chan, MSc", 
            "phone": "7804928869"
        }, 
        "overall_official": {
            "affiliation": "University of Alberta", 
            "last_name": "Ian M MacDonald, MD, CM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This is assessed by standard ocular examinations and vector dissemination and inflammation assays.", 
            "measure": "Number of patients with ocular and systemic adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "reference": [
            {
                "PMID": "18441370", 
                "citation": "Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, Dell'Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med. 2008 May 22;358(21):2240-8. Epub 2008 Apr 27."
            }, 
            {
                "PMID": "18774912", 
                "citation": "Hauswirth W, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L, Conlon T, Boye SL, Flotte TR, Byrne B, Jacobson SG. Phase I Trial of Leber Congenital Amaurosis due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results. Hum Gene Ther. 2008 Sep 7; [Epub ahead of print]"
            }, 
            {
                "PMID": "18441371", 
                "citation": "Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, Petersen-Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med. 2008 May 22;358(21):2231-9. Epub 2008 Apr 27."
            }, 
            {
                "PMID": "18209734", 
                "citation": "Bennicelli J, Wright JF, Komaromy A, Jacobs JB, Hauck B, Zelenaia O, Mingozzi F, Hui D, Chung D, Rex TS, Wei Z, Qu G, Zhou S, Zeiss C, Arruda VR, Acland GM, Dell'Osso LF, High KA, Maguire AM, Bennett J. Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther. 2008 Mar;16(3):458-65. doi: 10.1038/sj.mt.6300389. Epub 2008 Jan 22."
            }, 
            {
                "PMID": "19806502", 
                "citation": "MacLaren RE. An analysis of retinal gene therapy clinical trials. Curr Opin Mol Ther. 2009 Oct;11(5):540-6. Review."
            }, 
            {
                "PMID": "24439297", 
                "citation": "Maclaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L, Clark KR, During MJ, Cremers FP, Black GC, Lotery AJ, Downes SM, Webster AR, Seabra MC. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet. 2014 Jan 15. pii: S0140-6736(13)62117-0. doi: 10.1016/S0140-6736(13)62117-0. [Epub ahead of print]"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077361"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Alberta", 
            "investigator_full_name": "Ian M. MacDonald", 
            "investigator_title": "Professor and Chair, Department of Ophthalmology and Visual Sciences", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "This is assessed by Goldmann perimetry and microperimetry; measurements before and after vector delivery are compared.", 
                "measure": "Changes in visual field", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and up to 2 years following vector delivery"
            }, 
            {
                "description": "This is assessed by multifocal electrophysiology, full field scotopic threshold, spectral domain optical coherent tomography, fundus photography and fundus autofluorescence; measurements before and after vector delivery are compared.", 
                "measure": "Changes in visual function", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and 2 years following vector delivery"
            }
        ], 
        "source": "University of Alberta", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Alberta Innovates Health Solutions", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Canada Foundation for Innovation", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Canadian Institutes of Health Research  (CIHR)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Choroideremia Research Foundation Canada", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Foundation Fighting Blindness", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Imperial College London", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Oxford", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Ian M. MacDonald", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}